Node-positive Breast Cancer
11
5
7
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
18%
2 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (11)
Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer
Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
Axillary Node Dissection w or w/o LVB in Node Positive Breast Cancer Patients
Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer
Axillary Staging in Node Positive Breast Cancer Patients Receiving PST. SNB vs PET/MRI
OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk
TAD in Primary Breast Cancer With Initially ≥ 3 Suspicious Lymph Nodes
Evaluation of Targeted Axillary Lymph Node Dissection in Node Positive Breast Cancer Patients Post Neo Adjuvant Therapy
MUltimodal Targeted Axillary Surgery